CREATE Medicines
Vaccines
$122Mlatest round · Series B · May 2026 · 6 mo ago
2backers · 8VC, ARCH Venture Partners
200+team · employees, estimated range
2021founded
Overview
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable, off-the-shelf treatments for cancer, autoimmunity, and fibrosis.
Key facts
These are the key facts about CREATE Medicines on Alion as of Nov 13, 2026. CREATE Medicines is headquartered in Cambridge, United States. It was founded in 2021. The latest round is Series B of $122M, announced in 2026.
- Headquarters
- Cambridge, United StatesAlion company profile, updated Nov 13, 2026
- Founded
- 2021Alion company profile, updated Nov 13, 2026
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $122MSum of 1 equity round Alion knows
- Latest round
- Series B · $122M · May 14, 2026Press report · finance.yahoo.com
Funding and backers
Total raised
$122M
1 round on record
Latest round
$122M
Series B · May 2026 · 6 mo ago
Team
201-500
employees, estimated range
Backers
2
8VC, ARCH Venture Partners
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 14
Raised a round Series B $122M · led by Newpath Partners · YahooFinance
Oct 29, 2025
Launched CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo · timesargus.com
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2026 | $122M | Newpath Partners lead, ARCH Venture Partners lead | YahooFinance |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Positioned to deliver revolutionary off-the-shelf cancer vaccines. OUR CORE MISSION.
Hone Bio develops NanoPilot, a dual-targeting technology that enables cell-specific LNP delivery whilst actively blocking off-target…
Etherna pioneers in mRNA-LNP platforms, offering custom drug delivery platforms for tailored and innovative LNP drug delivery solutions.
Inside Therapeutics is a company specialized in providing system for nanoparticle synthesis or nanoparticle manufacturing using…
Novel Immunotherapies For Vulnerable Patients. At Belyntic, we are developing new therapies that harness the power of the patients' own…
Learn about BLINCYTO® (blinatumomab), a treatment for adults and children with CD-19 positive B-cell precursor acute lymphoblastic leukemia…
Financials
Total raised
$122M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | $122M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
ARCH Venture PartnersVia a fund
8VCVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
Read more
Report
CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
Read more
Report
CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University
CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University
Read more
Report
CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
Read more
Report
Financing at Create Medicines to advance in vivo CAR therapies
Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells
Read more
Report
Create Medicines raises $122M to bolster in vivo CAR-T therapies
The fresh funds will support the biotech
Read more
Report
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round, co-led by existing investors Newpath Partners, ARCH Venture Partners,
Read more
Report
CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Read more
Report
CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Read more
Report
CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, today announced new detailed data demonstrating complete B cell depletion in NHPs using its proprietary in vivo CAR-T platform. The results will be p
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
200-500 est. staff
300 Technology Square, Suite 203, Cambridge, MA, 02139, US
How to cite this page
Alion, "CREATE Medicines: key facts", as of Nov 13, 2026. https://alion.io/company/createmedicines
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0